These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23383727)

  • 21. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 22. The REFLEX study: a missed opportunity?
    Giovannoni G
    Lancet Neurol; 2012 Jan; 11(1):22-4. PubMed ID: 22146410
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing immunomodulatory therapy for MS patients: an integrated management model.
    Jeffery D; Bashir K; Buchwald L; Coyle P; Freedman M; Markowitz C; Rammohan K; Reder T; Sharief M; Wolinsky J
    J Neurol Sci; 2002 Sep; 201(1-2):89-90. PubMed ID: 12163200
    [No Abstract]   [Full Text] [Related]  

  • 24. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 25. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 26. Local reactions after subcutaneous injections of beta-interferon.
    van Rengen A; Goossens A
    Contact Dermatitis; 1998 Oct; 39(4):209. PubMed ID: 9817241
    [No Abstract]   [Full Text] [Related]  

  • 27. Shortcomings in pharmacy benefit forecasting--interferon beta products.
    Rich SJ; Meyer C
    J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
    [No Abstract]   [Full Text] [Related]  

  • 28. [Nursing service for MS patients].
    Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16518890
    [No Abstract]   [Full Text] [Related]  

  • 29. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 31. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis.
    Tuna Y; Başar O; Dikici H; Köklü S
    J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
    De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
    Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
    [No Abstract]   [Full Text] [Related]  

  • 37. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
    Kocer B; Nazliel B; Oztas M; Batur HZ
    Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
    [No Abstract]   [Full Text] [Related]  

  • 38. Local pain during REBIF injection is not due to acidic pH.
    Buttmann M; Goebeler M; Rieckmann P
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
    [No Abstract]   [Full Text] [Related]  

  • 39. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
    Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
    Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
    [No Abstract]   [Full Text] [Related]  

  • 40. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
    Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
    Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.